Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioHarvest Sciences's Debt-to-Equity or its related term are showing as below:
BHST'
s Debt-to-Equity Range Over the Past 10 Years
Min: -19.51 Med: -1.03 Max: 163.21
Current: 0.61
During the past 12 years, the highest Debt-to-Equity Ratio of BioHarvest Sciences was 163.21. The lowest was -19.51. And the median was -1.03.
BHST's Debt-to-Equity is ranked worse than 61.83% of 1745
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs BHST: 0.61
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioHarvest Sciences Debt-to-Equity Related Terms
BioHarvest Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioHarvest Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BHST vs BFNH, LSF, HAIN: Debt-to-Equity Comparison
For the Packaged Foods subindustry, BioHarvest Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioHarvest Sciences Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioHarvest Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioHarvest Sciences (BHST) has a Debt-to-Equity of 0.61 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioHarvest Sciences and its competitors. According to the industry distribution chart, BioHarvest Sciences ranks #1079 out of 1745 companies in the Consumer Packaged Goods industry, placing it in the top 61.8%.
Is BioHarvest Sciences' Debt-to-Equity too high?
BioHarvest Sciences' current Debt-to-Equity is 0.61. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. BioHarvest Sciences' value of 0.61 is 48.8% above this industry median. Based on the distribution chart, BioHarvest Sciences ranks #1079 out of 1745 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, BioHarvest Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Debt-to-Equity compare to BFNH and LSF?
According to the Consumer Packaged Goods industry distribution chart, BioHarvest Sciences ranks #1079 out of 1745 companies for Debt-to-Equity. This places BioHarvest Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.41. BioHarvest Sciences' value of 0.61 is 48.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,745 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioHarvest Sciences's current Debt-to-Equity of 0.61 is 48.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioHarvest Sciences and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioHarvest Sciences's current Debt-to-Equity is 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (BHST) is currently considered Possible Value Trap. The stock's GF Value™ is $8.60, compared to a current price of $1.92 — trading 77.7% below its estimated fair value. The current Debt-to-Equity is 0.61 and 48.8% above the Consumer Packaged Goods industry median of 0.41. BioHarvest Sciences' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioHarvest Sciences (BHST), the current Debt-to-Equity is 0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioHarvest Sciences (BHST) Overvalued in 2026?
Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued.
The current stock price of $1.92 is trading 77.7% below its estimated GF Value™ of $8.60.
GuruFocus considers BioHarvest Sciences to be Possible Value Trap.
Key valuation signals for BHST:
Debt-to-Equity: 0.61
GF Value™: $8.60 vs. price of $1.92 (77.7% below fair value)
Industry Position: 48.8% above the Consumer Packaged Goods median (#1079 of 1745)
No single metric tells the full story. See the BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
63GF Score
Get the complete analysis for BHST
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHST has been successfully added to your 
